Nat Med:治疗慢性病毒感染有新招

2015-03-26 佚名 生物谷

近日,来自美国的科学家在著名国际期刊nature medicine在线发表了他们的最新研究进展,他们发现慢性病毒感染如HIV等会导致细胞毒性T淋巴细胞功能衰退,在这个过程中前列腺素E2(PGE2)相关信号通路发挥了重要促进作用,因此,抑制PEG2或是治疗慢性病毒感染的一种有效手段。 目前,世界上有超过10%的人口正遭受HIV,HCV和HBV等慢性病毒感染的折磨,这几种疾病均可能引发严重并发症甚至死

近日,来自美国的科学家在著名国际期刊nature medicine在线发表了他们的最新研究进展,他们发现慢性病毒感染如HIV等会导致细胞毒性T淋巴细胞功能衰退,在这个过程中前列腺素E2(PGE2)相关信号通路发挥了重要促进作用,因此,抑制PEG2或是治疗慢性病毒感染的一种有效手段。

目前,世界上有超过10%的人口正遭受HIV,HCV和HBV等慢性病毒感染的折磨,这几种疾病均可能引发严重并发症甚至死亡。持续的抗原刺激会引起病毒特异性的细胞毒性T淋巴细胞(CTL)发生功能衰退,细胞死亡,导致HIV,HCV和HBV等病毒持续存在。除此之外,抗病毒性CTL会通过上调抑制性受体,如PD-1,自发性抑制它们对免疫病原体的限制作用。发现并阻断这些诱导CTL紊乱的信号途径可能有助于清除慢性病毒感染。

研究人员发现在慢性淋巴细胞性脉络丛脑膜炎病毒(LCMV)感染过程中前列腺素E2(PGE2)受体EP2和EP4在病毒特异性CTL中会发生上调,抑制CTL存活和正常功能发挥。他们证明联合阻断PGE2和PD-1信号途径在改善病毒控制,扩增具有正常功能的病毒特异性CTL细胞方面具有很好的效果。

综上所述,该项研究证明抑制PEG2既是一种靶向治疗慢性病毒感染的独立治疗手段,又能够与阻断PD-1信号联合作用治疗慢性病毒感染,具有重要应用前景。


原始出处:

Jonathan H Chen,Curtis J Perry, Yao-Chen Tsui,Matthew M Staron, Ian A Parish,Claudia X Dominguez,Daniel W Rosenberg& Susan M Kaech.Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection[J].Nature Medicine (2015) doi:10.1038/nm.3831.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880561, encodeId=541e1880561ec, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 16 05:51:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263984, encodeId=f9a81263984b5, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sat Mar 28 02:51:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606446, encodeId=af981606446cd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 28 02:51:00 CST 2015, time=2015-03-28, status=1, ipAttribution=)]
    2016-01-16 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880561, encodeId=541e1880561ec, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 16 05:51:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263984, encodeId=f9a81263984b5, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sat Mar 28 02:51:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606446, encodeId=af981606446cd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 28 02:51:00 CST 2015, time=2015-03-28, status=1, ipAttribution=)]
    2015-03-28 qjddjq
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880561, encodeId=541e1880561ec, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Jan 16 05:51:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263984, encodeId=f9a81263984b5, content=<a href='/topic/show?id=847353580bf' target=_blank style='color:#2F92EE;'>#慢性病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53580, encryptionId=847353580bf, topicName=慢性病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c49e75, createdName=qjddjq, createdTime=Sat Mar 28 02:51:00 CST 2015, time=2015-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606446, encodeId=af981606446cd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Mar 28 02:51:00 CST 2015, time=2015-03-28, status=1, ipAttribution=)]